Compass Ion Advisors LLC Sells 163 Shares of Stryker Co. (NYSE:SYK)

Compass Ion Advisors LLC reduced its stake in shares of Stryker Co. (NYSE:SYK) by 3.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,122 shares of the medical technology company’s stock after selling 163 shares during the period. Compass Ion Advisors LLC’s holdings in Stryker were worth $1,844,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of SYK. GSA Capital Partners LLP bought a new position in Stryker in the 3rd quarter worth approximately $362,000. Empowered Funds LLC boosted its holdings in Stryker by 6.5% in the 3rd quarter. Empowered Funds LLC now owns 6,504 shares of the medical technology company’s stock worth $2,350,000 after buying an additional 399 shares during the period. Thrivent Financial for Lutherans boosted its holdings in Stryker by 6.9% in the 3rd quarter. Thrivent Financial for Lutherans now owns 93,239 shares of the medical technology company’s stock worth $33,683,000 after buying an additional 5,995 shares during the period. Drive Wealth Management LLC boosted its holdings in Stryker by 10.3% in the 3rd quarter. Drive Wealth Management LLC now owns 720 shares of the medical technology company’s stock worth $261,000 after buying an additional 67 shares during the period. Finally, Caprock Group LLC boosted its holdings in Stryker by 2.8% in the 3rd quarter. Caprock Group LLC now owns 8,611 shares of the medical technology company’s stock worth $3,118,000 after buying an additional 234 shares during the period. 77.09% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on SYK shares. Canaccord Genuity Group raised their price objective on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Barclays raised their price objective on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Thursday, March 6th. Argus set a $450.00 price target on shares of Stryker in a report on Monday, February 3rd. Finally, Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $421.90.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Stryker Stock Performance

Stryker stock opened at $376.13 on Wednesday. The firm’s fifty day moving average price is $383.71 and its 200-day moving average price is $373.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock has a market cap of $143.52 billion, a P/E ratio of 48.47, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the firm posted $3.46 EPS. On average, equities research analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is presently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.